09:39 AM EDT, 06/06/2024 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) said Thursday that a new analysis of its phase 3 trial MAESTRO-NASH Rezdiffra trial showed that the treatment "improved key fibrotic features that are predictive of progression to decompensated cirrhosis."

Rezdiffra, a daily oral pill, met its primary endpoints for fibrosis improvement and resolution of nonalcoholic steatohepatitis, or NASH, the company said. Of the patients treated with Rezdiffra 100 mg, 80% showed improvement or stabilization of fibrosis, the company.

The company also said that 91% of patients treated with Rezdiffra achieved improvement or stabilization of liver stiffness at year three.

The trail is evaluating Rezdiffra against placebo in 1,759 patients,. Primary goals at week 52 were NASH resolution without worsened fibrosis and fibrosis improvement by at least one stage without worsened nonalcoholic fatty liver disease activity score.

Price: 235.70, Change: -0.27, Percent Change: -0.11